Breaking: FDA Greenlights Profound Medical's TULSA AI Module
Shares of Profound Medical Corp. (Nasdaq: PROF) surged by more than 10% in after-hours trading after it announced FDA clearance for its Thermal Boost module in conjunction with TULSA-PRO, which allows surgeons to treat various prostate conditions, including cancer and benign prostatic hyperplasia (BPH).
The Thermal Boost module, Profound's first FDA-cleared TULSA AI module, enables surgeons to temporarily increase the ablation target temperature in areas where advanced-stage cancer might be present, improving confidence in effective cancer cell ablation.
$PROF was trading at $10.94 in the extended session, up $1.04 (+10.51%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
© 2023 CRWE PRESS RELEASE. All Rights Reserved.
